Sonoma Pharmaceuticals, Inc. (SNOA) P/E Ratio History
Historical price-to-earnings valuation from 2014 to 2015
Loading P/E history...
SNOA Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Sonoma Pharmaceuticals, Inc. (SNOA) trades at a price-to-earnings ratio of -0.4x, with a stock price of $1.20 and trailing twelve-month earnings per share of $-1.97.
The current P/E is 102% below its 5-year average of 23.0x. Over the past five years, SNOA's P/E has ranged from a low of 11.6x to a high of 35.0x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 21.9x, SNOA trades at a 102% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 176.0x.
Relative to the broader market, SNOA trades at a notable discount to the S&P 500 median P/E of 24.9x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SNOA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SNOA P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $467M | 14.4Lowest | - | +105%Best | |
| $90B | 19.2 | - | +49% | |
| $8B | 21.7 | 6.87Best | +7% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
SNOA Historical P/E Data (2014–2015)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2015 Q3 | Wed Dec 31 2014 00:00:00 GM | $1287.00 | $47.10 | 27.3x | +19% |
| FY2015 Q2 | $2115.00 | $181.65 | 11.6x | -49% | |
| FY2015 Q1 | Mon Jun 30 2014 00:00:00 GM | $2781.00 | $153.20 | 18.2x | -21% |
| FY2014 Q4 | Mon Mar 31 2014 00:00:00 GM | $3393.00 | $96.90 | 35.0x | +52% |
Average P/E for displayed period: 23.0x
See SNOA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SNOA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SNOA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSNOA — Frequently Asked Questions
Quick answers to the most common questions about buying SNOA stock.
Is SNOA stock overvalued or undervalued?
SNOA trades at -0.4x P/E, below its 5-year average of 23.0x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does SNOA's valuation compare to peers?
Sonoma Pharmaceuticals, Inc. P/E of -0.4x compares to sector median of 21.9x. The discount suggests lower growth expectations or higher risk.
What is SNOA's PEG ratio?
SNOA PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2014-2015.